Graham J Emslie1, Karen Dineen Wagner2, Stan Kutcher2, Stan Krulewicz2, Regan Fong2, David J Carpenter2, Alan Lipschitz2, Andrea Machin2, Christel Wilkinson2. 1. Dr. Emslie is with the University of Texas Southwestern Medical Center at Dallas; Dr. Wagner is with the University of Texas Medical Branch at Galveston; Dr. Kutcher is with Dalhousie University in Halifax, Nova Scotia, Canada; Mr. Krulewicz and Drs. Fong, Carpenter, and Lipschitz are with GlaxoSmithKline, King of Prussia, PA; Ms. Machin and Ms. Wilkinson are with GlaxoSmithKline, Harlow, Essex, UK. Electronic address: graham.emslie@utsouthwestern.edu. 2. Dr. Emslie is with the University of Texas Southwestern Medical Center at Dallas; Dr. Wagner is with the University of Texas Medical Branch at Galveston; Dr. Kutcher is with Dalhousie University in Halifax, Nova Scotia, Canada; Mr. Krulewicz and Drs. Fong, Carpenter, and Lipschitz are with GlaxoSmithKline, King of Prussia, PA; Ms. Machin and Ms. Wilkinson are with GlaxoSmithKline, Harlow, Essex, UK.
Abstract
OBJECTIVE: To assess the efficacy and tolerability of paroxetine in pediatric major depressive disorder. METHOD: Subjects 7 to 17 years old with major depressive disorder receivedparoxetine (10-50 mg/day) or placebo for 8 weeks from 2000 to 2001. The primary efficacy measure was change from baseline in the Children's Depression Rating Scale-Revised total score at week 8 last observation carried forward). Safety was primarily assessed by spontaneous reporting of adverse events. RESULTS: A total of 206 patients (intent to treat) were randomized to paroxetine (n = 104) or placebo (n = 102). Week 8 Children's Depression Rating Scale-Revised total score adjusted mean changes from baseline for patients receiving paroxetine and placebo were -22.58 (SE 1.47) and -23.38 points (SE 1.60), respectively (0.80, 95% confidence interval -3.09 to 4.69, p = 0.684). Increased cough (5.9% versus 2.9%), dyspepsia (5.9% versus 2.9%), vomiting (5.9% versus 2.0%), and dizziness (5.0% versus 1.0%) occurred in >or=5% of the paroxetine group and at least twice that of the placebo group. Six of 104 (5.8%) paroxetine patients reported serious adverse events compared to 1 placebo patient (1.0%). The incidence of adverse events of suicidal behavior and/or ideation while taking study medication (excluding taper) was 1.92% (2/104) for paroxetine versus 0.98% (1/102) for placebo. CONCLUSIONS:Paroxetine was not shown to be more efficacious than placebo for treating pediatric major depressive disorder.
RCT Entities:
OBJECTIVE: To assess the efficacy and tolerability of paroxetine in pediatric major depressive disorder. METHOD: Subjects 7 to 17 years old with major depressive disorder received paroxetine (10-50 mg/day) or placebo for 8 weeks from 2000 to 2001. The primary efficacy measure was change from baseline in the Children's Depression Rating Scale-Revised total score at week 8 last observation carried forward). Safety was primarily assessed by spontaneous reporting of adverse events. RESULTS: A total of 206 patients (intent to treat) were randomized to paroxetine (n = 104) or placebo (n = 102). Week 8 Children's Depression Rating Scale-Revised total score adjusted mean changes from baseline for patients receiving paroxetine and placebo were -22.58 (SE 1.47) and -23.38 points (SE 1.60), respectively (0.80, 95% confidence interval -3.09 to 4.69, p = 0.684). Increased cough (5.9% versus 2.9%), dyspepsia (5.9% versus 2.9%), vomiting (5.9% versus 2.0%), and dizziness (5.0% versus 1.0%) occurred in >or=5% of the paroxetine group and at least twice that of the placebo group. Six of 104 (5.8%) paroxetinepatients reported serious adverse events compared to 1 placebo patient (1.0%). The incidence of adverse events of suicidal behavior and/or ideation while taking study medication (excluding taper) was 1.92% (2/104) for paroxetine versus 0.98% (1/102) for placebo. CONCLUSIONS:Paroxetine was not shown to be more efficacious than placebo for treating pediatric major depressive disorder.
Authors: Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Bret R Rutherford; Joel R Sneed; Jane M Tandler; David Rindskopf; Bradley S Peterson; Steven P Roose Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-06-15 Impact factor: 8.829
Authors: Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596